Increase in Serum Magnesium Level in Haemodialysis Patients Receiving Sevelamer Hydrochloride

Mitsopoulos, Efstathios; Griveas, Ioannis; Zanos, Stavros; Αναγνωστόπουλος, Κωνσταντίνος; Giannakou, Anastasia; Pavlitou, Aikaterini; Sakellariou, G

doi:10.1007/s11255-004-7135-5

Cited by 24 publications

(13 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found that HD patients receiving sevelamer have a significant increase in serum Mg. This increase in serum Mg is associated with a reduction in the iPTH level (r = -0.40, p = 0.016) [84] . It can be speculated that the rise in serum Mg levels might also contribute to the much debated superiority of sevelamer in suppressing vascular calcifications compared to other phosphate binders.…”

Section: The Effect Of Mg On Athero-and Arteriosclerosis: Vascular Camentioning

confidence: 91%

“…The authors concluded that 'hypermagnesemia might be associated with retardation or improvement of arterial calcifications in peritoneal dialysis patients' [64] . Finally, Mitsopoulos et al [84] investigated the effect of sevelamer on serum Mg in HD patients to assess the association of Mg levels with iPTH and lipid profiles. They found that HD patients receiving sevelamer have a significant increase in serum Mg.…”

Section: The Effect Of Mg On Athero-and Arteriosclerosis: Vascular Camentioning

confidence: 99%

See 1 more Smart Citation

Magnesium in Chronic Kidney Disease: Challenges and Opportunities

Kanbay¹,

Goldsmith

Uyar

et al. 2010

Blood Purif

View full text Add to dashboard Cite

Cardiovascular disease is the leading cause of mortality and morbidity in patients with chronic kidney disease, which is partly explained by the fact that 40–70% of patients receiving dialysis have significant coronary artery disease. Recent clinical studies have shown that lower serum magnesium (Mg) levels are associated with vascular calcification and cardiovascular mortality among patients with end-stage renal disease (ESRD). On the other hand, hypermagnesemia inhibits parathyroid hormone secretion, which is considered an important independent risk factor for vascular calcification, left ventricular hypertrophy and mortality in ESRD patients. Finally, increasing evidence points towards a link between Mg and cardiovascular disease, even in subjects without chronic kidney disease. The purpose of this review was to critically review the current literature examining the effects of plasma Mg levels on cardiovascular disease and parathyroid hormone homeostasis in ESRD, and renal transplant patients.

show abstract

Section: The Effect Of Mg On Athero-and Arteriosclerosis: Vascular Camentioning

confidence: 91%

Section: The Effect Of Mg On Athero-and Arteriosclerosis: Vascular Camentioning

confidence: 99%

Magnesium in Chronic Kidney Disease: Challenges and Opportunities

Kanbay¹,

Goldsmith

Uyar

et al. 2010

Blood Purif

View full text Add to dashboard Cite

show abstract

“…It seems plausible to speculate that this effect of sevelamer depends on its adsorptive action on some substances other than P. Free fatty acids in the intestinal lumen may combine with Mg to form non-absorbable soaps. Therefore, Mitsopoulos et al speculated that sevelamer binds biliary salts, thereby increasing the quantity of free Mg available for intestinal absorption [84]. On the other hand, Nagano et al reported the contribution of magnesium stearate, which is included as a pharmaceutical excipient in phosphate binders, to increases in serum Mg levels [87].…”

Section: Mg-containing Laxativesmentioning

confidence: 99%

Cardiovascular disease, mortality, and magnesium in chronic kidney disease: growing interest in magnesium-related interventions

Ikee¹

2018

Ren Replace Ther

View full text Add to dashboard Cite

Magnesium (Mg) is an essential element that plays pivotal roles in a number of biological processes in the human body. Hypomagnesemia is involved in the pathophysiology of hypertension, vascular calcification, and metabolic derangements including diabetes mellitus and dyslipidemia, which are all risk factors for cardiovascular disease, the leading cause of mortality and morbidity in patients with chronic kidney disease (CKD). Hypomagnesemia is also associated with the development and progression of CKD. As CKD advances, renal Mg excretion decreases and hypermagnesemia emerges in end-stage renal disease (ESRD). In addition, dialysates with high Mg concentrations, which were used in the early era of dialysis therapy, increased the risk of hypermagnesemia, and thus, the dialysate Mg composition has since been reduced. Accordingly, dialysis patients in the modern era commonly have normomagnesemia or even hypomagnesemia. The relationships between hypomagnesemia and cardiovascular disease and mortality have been increasingly reported in observational studies in CKD/ESRD. However, these relationships may be attenuated by a patient's race or region. Although dialysates with higher Mg concentrations or Mg-containing phosphate binders appear to be promising in this setting, only a few interventional studies have examined the effects of Mg supplementation on cardiovascular lesions. Furthermore, the effects of Mg supplementation on mortality have not yet been investigated as a primary end-point in randomized controlled trials. Further studies are required in order to establish the efficacy and safety of Mg in CKD patients.

show abstract

“…It is well tolerated except for an increased incidence of metabolic acidosis [7]. Other side effects include abdominal pain, diarrhea, nauseavomiting, muscle cramps, hypocalcemia, headache and hypermagnesemia [8]. In children with end stage renal disease, it has been used in doses of 100 mg/kg/day to 130 mg/kg/day, every 8 hours [7,9].…”

Section: Discussionmentioning

confidence: 99%

Sevelamer hydrochloride for tumor lysis syndrome-related hyperphosphatemia

Prasada

2015

Indian Pediatr

View full text Add to dashboard Cite

Increase in Serum Magnesium Level in Haemodialysis Patients Receiving Sevelamer Hydrochloride

Cited by 24 publications

References 24 publications

Magnesium in Chronic Kidney Disease: Challenges and Opportunities

Magnesium in Chronic Kidney Disease: Challenges and Opportunities

Cardiovascular disease, mortality, and magnesium in chronic kidney disease: growing interest in magnesium-related interventions

Sevelamer hydrochloride for tumor lysis syndrome-related hyperphosphatemia

Contact Info

Product

Resources

About